Why Is Barclays Optimistic about Jazz Pharmaceuticals?
Barclays on Jazz Pharmaceuticals
One of Barclays’ (BCS) top picks for the health care sector (XLV) is Jazz Pharmaceuticals (JAZZ). The firm expects a 26% upside for the stock from its level of $158.80 on June 23, 2017, and set a target price of $200.
Interested in XLV? Don't miss the next report.
Receive e-mail alerts for new research on XLV
According to Barclays, Jazz Pharmaceuticals focuses on new product developments that will drive its growth. Barclays wrote, “JAZZ’s recent settlement with first-filer Hikma preserves significant economics around the Xyrem franchise and delays generic entry until 2026.”
Jazz Pharmaceuticals’ performance
Jazz Pharmaceuticals is currently trading at $155.20. Its 52-week high is $163.75, and its 52-week low is $95.80. It’s currently trading at a price-to-earnings multiple of 23.44x. On a year-to-date basis, the stock has returned nearly 39.5% as of June 27, 2017. The stock has returned nearly 11% in the last one year. The stock posted strong revenue growth in 2014 and 2015. The Health Care Select Sector SPDR ETF (XLV), which tracks the performance of the health care sector, returned nearly 15%, on a year-to-date basis, as of June 27, 2017. Pfizer (PFE) and Amgen (AMGN) have returned nearly -3% and 11%, respectively, over the past year.
You may be interested to read, Why BlackRock Is So Optimistic about US Stocks.